about
Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologicsAlemtuzumab for Multiple Sclerosis.Alemtuzumab for the treatment of multiple sclerosisComparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosisInterferon-β therapy and risk of thrombocytopenia in multiple sclerosis patients.Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.3,3'-diindolylmethane ameliorates experimental autoimmune encephalomyelitis by promoting cell cycle arrest and apoptosis in activated T cells through microRNA signaling pathways.Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer.Monoclonal antibodies as disease modifying therapy in multiple sclerosis.Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?Current evaluation of alemtuzumab in multiple sclerosis.Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis.Drug safety evaluation of alemtuzumab for multiple sclerosis.Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.Therapeutic management of severe relapses in multiple sclerosis.
P2860
Q26826924-C6E51600-2584-460E-9C0D-CF51AFE51FDDQ28069730-2055196B-FBE5-4C3D-BFCA-7C2E76ED6D9BQ28080506-4725E6A8-7F09-42C4-8D6A-D612F9E9F9A5Q28081636-580DEBCD-6603-4D48-A3E5-50CBA0027B7BQ33424731-B28E5175-5389-46FB-8154-0D5F9CD757A9Q33440086-CF933178-D8FA-45B9-81FF-90F5B42EAC68Q33944014-4FE2E92D-5CDA-4A07-AC0B-C3246339BAF6Q36503756-6B0F206C-408B-4A32-865B-D7788CF30EAFQ37668086-357FB1C5-2E47-43E7-8770-8CDDEB797B72Q38152451-416C1B07-5D9D-40DE-BD6D-0ED912FC0810Q38167350-32F23DD6-FFE6-4943-B275-6ED2E43FEE7DQ38194115-669D59A4-89D0-490B-A81D-458058EBDC06Q38220740-1CA766F8-8DDE-4A89-9484-50579FF9252BQ38619696-1F4E5F56-F1DA-485C-B108-F43B7B45E087Q38650602-ADF83D52-AEDE-4FD0-A019-2632BD39E293Q39026942-6A94E4AB-5F1A-4F2F-B30A-A1D3B1E613D8
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Alemtuzumab treatment of multiple sclerosis.
@ast
Alemtuzumab treatment of multiple sclerosis.
@en
type
label
Alemtuzumab treatment of multiple sclerosis.
@ast
Alemtuzumab treatment of multiple sclerosis.
@en
prefLabel
Alemtuzumab treatment of multiple sclerosis.
@ast
Alemtuzumab treatment of multiple sclerosis.
@en
P356
P1476
Alemtuzumab treatment of multiple sclerosis.
@en
P2093
Alasdair J Coles
P356
10.1055/S-0033-1343797
P577
2013-02-01T00:00:00Z